The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral Therapy Get access Arrow

Six people with HIV received infusions of 2 × 107 HIV-specific T cells/m² with vorinostat 400 mg, and 3 eople with HIV received infusions of 10 × 107 HIV-specific T cells/m² with vorinostat. The frequency of persistent HIV by multiple assays including quantitative viral outgrowth assay of resting CD4+ T cells was measured before and after study therapy.